A Study of the possible neuroprotective effect of βeta-Adrenergic receptor agonist in rotenone induced Parkinson’s disease in rats (PO 3.4.3) / (Record no. 169954)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05930namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033402.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250104s2024 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.704 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.704 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.Ph.D.2024.Ha.S |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Haneen Yahia Mohamed, |
| Preparation | preparation. |
| 245 12 - TITLE STATEMENT | |
| Title | A Study of the possible neuroprotective effect of βeta-Adrenergic receptor agonist in rotenone induced Parkinson’s disease in rats (PO 3.4.3) / |
| Statement of responsibility, etc. | by Haneen Yahia Mohamed ; supervision of Dr / Mohammed Farag El -Yamany, Dr/ Mostafa Adel Mohamed Rabie. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | / (PO 3.4.3) دراسة التأثير الوقائي العصبي المحتمل لمستضاد مستقبل بيتا أدرينالين في مرض الشلل الرعاش المحدث بالروتينون في الجرذان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 107 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 88-107. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | β2-adrenoreceptors (β2-AR have been identified recently as regulators of the α-synuclein gene (SNCA), one of the key milieus endorsed in injury of dopamine neurons in Parkinson's disease (PD). Accumulation of α-synuclein leads to mitochondrial dysfunction via downregulation of mitophagy proteins (PINK and PARKIN) and inhibition of mitochondria biogenesis (PGC-1α) along with an increase in the master inflammatory regulator NF-κB p65 production that provokes neurodegeneration and diminishes neuroprotective signaling pathway (PI3k/Akt/CREB/BDNF). Recently, formoterol exhibited a promising neuroprotective effect against neurodegenerative conditions associated with brain inflammation. Therefore, the present investigation aimed to unveil the possible neuroprotective activity of formoterol, β2-AR agonist, against rotenone-induced PD in rats. Rats received rotenone (1.5 mg/kg; s.c.) every other day for 3 weeks and cured with formoterol (25 μg/kg/day; i.p.) 1 hr. after rotenone administration, starting from day 11. Formoterol treatment succeeded in upregulating β2-adrenoreceptor expression in PD rats and preserving the function and integrity of dopaminergic neurons as witnessed by enhancement of muscular performance in tests, open field, grip strength-meter, and Rotarod, besides the increment in substantia nigra and striatal tyrosine hydroxylase immunoexpression. In parallel, formoterol boosted mitophagy by activation of PINK1 and PARKIN and preserved mitochondrial membrane potential. Additionally, formoterol stimulated the neuro-survival signaling axis via stimulation of PI3k/pS473-Akt/pS133-CREB/BDNF cascade to attenuate neuronal loss. Noteworthy formoterol reduces neuro-inflammatory status by decreasing NFκBp65 immunoexpression and TNF-α content. Finally, formoterol's potential as a stimulant therapy of mitophagy via the PINK1/PARKIN axis and regulation of mitochondrial biogenesis by increasing PGC-1α to maintain mitochondrial homeostasis along with stimulation of PI3k/Akt/CREB/BDNF axis. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | يُعد مرض الشلل الرعاش أحد أكثر الاضطرابات العصبية التنكسية شيوعًا ويتميز باضطرابات الوقوف والمشية والتوازن. تم ربط ألفا سينوكلين بكل من الأشكال المتفرقة والعائلية للمرض. علاوة على ذلك ، يوجد ألفا سينوكلين في أجسام ليوي ، وقد تم ربط السمة المرضية العصبية لمرض الشلل الرعاش على نطاق واسع بمسارات السمية العصبية التي تؤدي في النهاية إلى التنكس العصبي . يمكن محاكاة مرض الشلل الرعاش تجريبياً عن طريق أخذ الروتينون التي تحفز تكوين شوائب ألفا سينوكلين ، مع نواة كثيفة ومحيط ليفي يشبه تلك التي لوحظت في مرض الشلل الرعاش مما يؤدي إلى انخفاض في الأداء الحركي وارتفاع مستويات السيتوكينات المسببة للالتهابات (عامل نخر الورم ألفا) <br/>ينظم تنشيط مستقبلات البيتا التعبير الجيني لـ ألفا سينوكلين في نماذج حيوانية مختلفة وفي المختبر من مرض الشلل الرعاش ، ويعزز تكوين العصب الحُصيني. العلاج باستخدام ناهضات مستقبلات بيتا الأدرينالية مثل الفورميترول ، وهو ناهض بيتا يمكنه العبور من حاجز الدم في الدماغ ، وبذلك يقلل من التعبير عن جين ألفا سينوكلين عبر أستيل هيستون -3 ليسين -27 لمحفزه ومُحسِّنه ويحفز أيضًا تخليق عامل التغذية العصبية المشتق من الدماغ في الخلايا النجمية والخلايا العصبية في المختبر وفي الجسم الحي. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs effects and interactions |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | β2-adrenoreceptor |
| -- | α-synuclein |
| -- | mitophagy |
| -- | formoterol |
| -- | PI3K/Akt |
| -- | BDNF |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohammed Farag El -Yamany |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mostafa Adel Mohamed Rabie |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Mohammed Farag El -Yamany |
| -- | Mostafa Adel Mohamed Rabie |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology & Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 04.01.2025 | 90143 | Cai01.08.09.Ph.D.2024.Ha.S | 01010110090143000 | 04.01.2025 | 04.01.2025 | Thesis |